Invasive Bladder Urothelial Carcinoma — Trials

Invasive Bladder Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

45 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 15
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (8)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07332351	Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial(TRIFECTA)	not yet recruiting	Phase 2	33	University of WashingtonOTHER	1	Sep 17, 2026	clinicaltrials
NCT07822373	A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer(PRESERVE)	not yet recruiting	Phase 2	25	University of Utah